According to a Merrill Lynch analyst, AMG 706 appears to be neither as safe or as efficacious as Sutent. The key data in his conclusion: 3% patient response for AMG 706 vs. 7% response in P3 Sutent trials.
One thing to keep in mind: all trials data relates to GIST, which is probably not the target market for AMG 706 (or Sutent, for that matter.)
Showing posts with label AMG 706. Show all posts
Showing posts with label AMG 706. Show all posts
Monday, November 06, 2006
AMG 706 news
First disclosure of P2 results from Amgen's small molecule multi-TK inhibitor, targeting all VEFRs, PDGF, and Kit. Interesting to see that the first indication is (was?) Gleevec-resistant GIST., so it would seem that the Kit targeting is the first (best?) application.
Other interesting details:
-daily dosing, so little tox worries.
-125mg dose - seems large, indicating reduced potency?
-still only about a third of all patients demonstrated a clinical response.
-pretty high rate of adverse reactions (nausea, hypertensions,etc.) affecting it would seem nearly all participants.
-explicit mention of further inications/trials (NSCLC and breat, in particular) and monotherapy targeting of medullary thyroid cancer, which has no effective treatment.
IN all, AMG 706 sounds like a very competitive product.
Other interesting details:
-daily dosing, so little tox worries.
-125mg dose - seems large, indicating reduced potency?
-still only about a third of all patients demonstrated a clinical response.
-pretty high rate of adverse reactions (nausea, hypertensions,etc.) affecting it would seem nearly all participants.
-explicit mention of further inications/trials (NSCLC and breat, in particular) and monotherapy targeting of medullary thyroid cancer, which has no effective treatment.
IN all, AMG 706 sounds like a very competitive product.
Subscribe to:
Posts (Atom)
